customer login
InoveonIfa Systems AG

Ask your doctor about Inoveon's iScan evaluation!

Inoveon's iScan is the best way to detect and evaluate diabetic retinopathy and macular edema - a major cause of vision loss in patients with diabetes.


Because it is located in your primary care physician's office it is convenient to get this testing done. Doing so, insures you are getting the best care to protect your sight and maintain your quality of life.

A standard report with the results of your iScan will be sent to your doctor within 2 working days. This specially formatted report provides an iScore The report is color coded according to management recommendations to accurately stage both diabetic retinopathy and macular edema in each eye. The scores follow the scale used in NIH clinical trials so they can be followed over time to see if disease is progressing.  


Protect your vision with the iScan from the experts in detecting, staging and monitoring diabetic retinopathy and macular edema

Diabetic retinopathy occurs when the blood vessels that nourish the retina deteriorate. As they deteriorate, portions of the blood vessels can leak fluid into the retinal tissue.

This leakage may also cause swelling in the macula known as macular edema. The iScan test uses 3-D imaging to accurately stage both proliferative diabetic retinopathy and macular edema.


The iScan procedure scans 100% of the retinal area recommended by the NIH protocols. It images seven specific areas of each eye (see image above) in 3D to help your physician find diabetic changes early and provide timely, vision-saving care. After checking your vision and dilating your eyes, the iScan technician will image different parts of each eye. These images are sent for specialized analysis, and a report is sent back to your doctor the next day.

Because diabetic retinopathy progresses without symptoms until vision loss begins, evidence-based guidelines call for annual dilated retinal exams (DRE) to be performed on all patients with diabetes.


These regular periodic evaluations identify patients with high-risk disease that would benefit from treatment. However, less than half of known diabetic patients are evaluated for DR as recommended.